The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1443
Sorafenib (Nexavar) for Thyroid Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the use of the oral multikinase inhibitor sorafenib (Nexavar – Bayer) for treatment of locally recurrent or metastatic, progressive, differentiated thyroid cancer (papillary or follicular) refractory to radioactive iodine treatment. Sorafenib was approved earlier for treatment of advanced renal cell and unresectable hepatocellular cancer.1

STANDARD TREATMENT — Surgery and radioactive iodine are the preferred treatments for thyroid cancer. When these fail, cytotoxic drugs have not been very effective and kinase inhibitors including sorafenib have been used. Two other kinase inhibitors, vandetanib (Caprelsa) and cabozantinib (Cometriq), were approved earlier for treatment of advanced medullary thyroid cancer, which is relatively rare.2

CLINICAL STUDIES — A meta-analysis of ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Sorafenib (Nexavar) for Thyroid Cancer
Article code: 1443c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian